TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06651567: A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study of the Efficacy, Safety, and Tolerability of ITI-1284 in Patients With Agitation Associated With Alzheimer's Dementia

Sponsor: Intra-Cellular Therapies, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 320 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$5,276,800

Rescue Site Savings

+$3,492,000

Unlock Full NCT06651567 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06651567 Rescue Dossier →